Pharsight

Jaypirca patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10695323 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(12 years from now)

US10342780 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10464905 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(12 years from now)

US10918622 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(12 years from now)

Jaypirca is owned by Loxo Oncol.

Jaypirca contains Pirtobrutinib.

Jaypirca has a total of 4 drug patents out of which 0 drug patents have expired.

Jaypirca was authorised for market use on 27 January, 2023.

Jaypirca is available in tablet;oral dosage forms.

Jaypirca can be used as adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (cll/sll) who have received at least two prior lines of therapy, including a btk inhibitor and a bcl-2 inhibitor.

Drug patent challenges can be filed against Jaypirca from 27 January, 2027.

The generics of Jaypirca are possible to be released after 16 December, 2036.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-424) Jan 27, 2030
New Chemical Entity Exclusivity(NCE) Jan 27, 2028
Orphan Drug Exclusivity(ODE-451) Dec 01, 2030

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using PIRTOBRUTINIB ingredient

NCE-1 date: 27 January, 2027

Market Authorisation Date: 27 January, 2023

Treatment: Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (cll/sll) who have received at least two prior lines of therapy, including a btk inhibitor and a bcl-2 inhibitor

Dosage: TABLET;ORAL

More Information on Dosage

JAYPIRCA family patents

Family Patents